Print
|
Close
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
Active:
Yes
Cancer Type:
Head and Neck Cancer
Unknown Primary
NCT ID:
NCT06496178
Trial Phases:
Phase III
Protocol IDs:
MCLA-158-CL02 (primary)
NCI-2024-06206
2023-510322-32
2023-510322-32-00
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Merus B.V.
NCI Full Details:
http://clinicaltrials.gov/show/NCT06496178
Summary
This is a phase 3 open-label, randomized, controlled, multicenter study to compare
petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and
third-line treatment of incurable metastatic/recurrent disease.
Objectives
This is a phase 3 open-label, randomized, controlled, multicenter study to compare
petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and
third-line treatment of incurable metastatic/recurrent disease. HNSCC patients must have
progressive disease (PD) on or after anti-PD-1 therapy and platinum-containing therapy.
Patients treated with platinum-containing therapy only in the adjuvant setting, or in the
context of multimodal therapy for locally advanced disease, should have PD within 6
months of the last dose of platinum-containing therapy.
Treatment Sites in Georgia
Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.